Key Takeaways
- 19.5% YoY growth despite API headwinds: Revenue grew strongly even as declining API prices pressured the CDMO business, with early signs of price stabilization now visible.
- GST benefit cut reshapes Jammu economics: The central government reduced the GST incentive from 12% to 5%, requiring nearly double the sales to capture the same absolute benefit and forcing a redefinition of customer pricing.
- Branded generics accelerated sharply: The segment grew 31% in Q2 and 43% in H1, driven by an expanding product basket and enhanced marketing efforts.
- Management doubled down on the 3-year doubling target: The company reiterated its post-IPO commitment to double top line, EBITDA and PAT in the next three years, seeing no challenge in achieving it.
- What to watch next quarter: Whether Jammu's EBITDA breakeven timeline shifts due to the GST change, the pace of API price recovery, and any quantification of the GST impact on margins once pricing is redefined.
Revenue Growth & Segment Dynamics
- Group-level volume healthy: Volume growth was strong across the group, reflecting expanding market presence and customer demand, even as API price declines created a headwind on the CDMO top line.
- CDMO resilient at 15% growth: The CDMO business grew 15% in Q2 and 12% in H1 despite temporary pressure from lower API prices, with resilience attributed to client base diversity and product portfolio strength.
- Branded generics the standout: The segment recorded 31% growth in Q2 and 43% in H1, driven by an expanded product basket and enhanced marketing efforts.
- Volume vs price split exposed: On an ex-Jammu basis at the Baddi facilities, volume growth was 8% to 10% while the negative price range was 10% to 12%, revealing the extent of API price erosion.
- API prices may be bottoming: Early signs of a reversal or bottoming-out in API pricing have emerged, with speculation that the coming financial year should not see further degradation, though this depends on supply-demand dynamics and capacity availability.
- Segment reclassification underway: Effective 1st April 2025, business areas were reclassified between CDMO and Branded Generics, meaning previous segment breakups may not be available for comparison.
Jammu Facility: GST Reset & Ramp-Up
- GST incentive halved: The central government reduced the GST rate on pharmaceutical formulations from 12% to 5%, cutting the Jammu facility's direct GST incentive benefit from 12% to 5%. The absolute quantum of benefit remains the same, but achieving it now requires sales of roughly ₹1,400 crores versus ₹650 crores previously.
- Pricing will be redefined: Since most business is B2B, some percentage of the GST benefit reduction will be passed to customers, and pricing will be redefined. Management stated the 7% margin loss will not fully transfer to the P&L.
- FY26 trajectory held at ₹250 crores: Despite API corrections, management maintained the Jammu facility is still on a clear trajectory of ₹250 crores for FY26.
- Longer-term ambition intact: The facility is expected to reach revenue of more than ₹1,000 crores in 2 to 3 years, with a 3 to 4 year plan to achieve that level. At 65% to 70% capacity utilization, 4 to 5 years out, Jammu should reach north of ₹1,400 crores.
- EBITDA breakeven under reassessment: The facility is nearing EBITDA breakeven on current turnover, but management is reassessing EBITDA levels due to the changed GST dynamics and will comment in coming quarters.
- Client onboarding progressing: Several prominent CDMO clients have completed audits and reviewed data from stability batches and process validation at Jammu, with business operations commenced with some and discussions at advanced stages with others.
Lohariwala: "Simply, it's like a half a glass is full and half a glass is empty. So if you see from the bottom, the half a glass is full still, we have the 5% benefit. And if you see from the top, half a glass is empty so 7% margin is loose."
Margin Outlook & Sustainability
- B2B margin band established: In the B2B business, margins have stabilized between 13% to 17% over a long trajectory, with a median sustainable margin of 15%. Management expects the same trajectory from Jammu once turnover stabilizes at breakeven.
- GST impact not fully quantifiable yet: When an analyst asked if the GST reimbursement impact would be roughly ₹30 to 50 crores over the next couple of years, management declined to confirm, stating "we cannot measure that impact in this way" and that pricing will be redefined.
- 15% margin optimism sustained: Despite the GST reduction, management remains optimistic that the 15% margin should sustain in the long term, with pricing to be redefined in the B2B business.
- Working capital elevated on growth: The increase in working capital investment was attributed mainly to sustaining the ongoing growth pattern and future growth projections, with days expected to normalize once sales improve.
Regulatory Milestones & Compliance
- Two international inspections cleared: The cephalosporin plant in Baddi was successfully inspected by the UK-MHRA, and the Jammu facility was successfully inspected by Ukraine's SMDC.
- Regulatory pressure seen as opportunity: Management acknowledged increased compliance pressure from domestic regulators but framed it as a differentiator, noting that companies complying with standards and staying ahead of the curve will see a brighter future.
- No comment on approval timelines: When asked about longer approval timelines due to increased compliance pressure, management declined to comment on individual issues.
Lohariwala: "And we see the challenge and opportunity both in all these regulatory updates. But those companies who are complying with the standards and put themselves ahead of the curve, will see a bright and better future."
Acquisitions & Capital Allocation
- Sharon Bio integrating well: The acquisition has been growing steadily along with the company's growth projection, with its contribution steadily increasing in sync with the overall growth trajectory. Management described it as a good acquisition.
- Sharon contribution undisclosed: When asked for Sharon Bio's specific contribution to the top line for the quarter, management deflected with a general statement about steady growth and did not provide the figure.
- Branded generics domestic split unavailable: When asked for the contribution of the domestic Branded Generics business to Q2 top line, management declined citing the segment reclassification effective 1st April 2025.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Top-line doubling | Double top line, EBITDA and PAT from post-IPO base | Next 3 years |
| Jammu revenue | Reach more than ₹1,000 crores | 2 to 3 years |
| Jammu peak revenue | North of ₹1,400 crores at 65% to 70% capacity utilization | 4 to 5 years |
| Jammu FY26 trajectory | ₹250 crores revenue despite API corrections | FY26 |
| Margin sustainability | 15% margin sustained in B2B business, including Jammu post-stabilization | Long term |
| API pricing | Speculation of no further price degradation | Coming financial year |
| Jammu EBITDA breakeven | Reassessment underway; will comment | Coming quarters |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Consolidated revenue | ₹380.4 crores, +19.5% YoY |
| H1 FY26 consolidated revenue | ₹731.9 crores, +19.5% YoY |
| EBITDA | ₹56.1 crores, +8% YoY (vs ₹51.9 crores in Q2 FY25) |
| H1 FY26 EBITDA | ₹112.6 crores, +17% YoY (vs ₹96.2 crores in H1 FY25) |
| EBITDA margin | ~15%, within estimated level |
| PAT margin | ~8% |
| CDMO business revenue | ₹265.7 crores, +15% YoY |
| CDMO business H1 FY26 revenue | ₹515.2 crores, +12% YoY |
| Branded Generics business revenue | ₹114.6 crores, +31% YoY |
| Branded Generics business H1 FY26 revenue | ₹216.7 crores, +43% YoY |
| Export revenue mix | 30% of consolidated revenue |
| Jammu facility H1 FY26 revenue | ~₹120 crores |
| Jammu facility projected annual run-rate | ₹240–250 crores |
| Jammu facility peak revenue potential | North of ₹1,400 crores, at 65–70% capacity utilisation |
| Total investment in Jammu facility | ₹480+ crores |
| Volume growth, ex-Jammu (Baddi) | 8–10% |
| Price decline, ex-Jammu (Baddi) | 10–12% negative |
| GST incentive maximum quantum (Jammu) | ₹75–80 crores |
| Working capital days increase | +12 days |
| Normal working capital days level | 85–90 days |